Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash & Equivalents: 2021-2025

Historic Cash & Equivalents for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Sep 2025 value amounting to $225.2 million.

  • Amylyx Pharmaceuticals' Cash & Equivalents rose 213.45% to $225.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.2 million, marking a year-over-year increase of 213.45%. This contributed to the annual value of $77.4 million for FY2024, which is 54.53% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Cash & Equivalents of $225.2 million as of Q3 2025, which was up 287.67% from $58.1 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' 5-year Cash & Equivalents high stood at $247.8 million for Q2 2023, and its period low was $50.2 million during Q4 2021.
  • In the last 3 years, Amylyx Pharmaceuticals' Cash & Equivalents had a median value of $114.6 million in 2023 and averaged $127.8 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 267.38% in 2023, then slumped by 69.73% in 2024.
  • Amylyx Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $50.2 million in 2021, then climbed by 24.58% to $62.5 million in 2022, then surged by 172.21% to $170.2 million in 2023, then slumped by 54.53% to $77.4 million in 2024, then soared by 213.45% to $225.2 million in 2025.
  • Its last three reported values are $225.2 million in Q3 2025, $58.1 million for Q2 2025, and $59.8 million during Q1 2025.